-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In early March, due to concerns that the AstraZeneca vaccine may cause blood clots in the human body, Denmark, Norway, Iceland, Italy, Romania and many other countries temporarily suspended the AstraZeneca vaccine.
In this regard, AstraZeneca retorted in a statement on March 14 that there is no evidence that there is a connection between the vaccine and thrombosis, and insisted that its new crown vaccine is safe.
On March 22, local time, AstraZeneca’s official website further announced the interim analysis results of the phase 3 clinical trial of the recombinant adenovirus vector vaccine ZAD1222 developed in cooperation with the University of Oxford, and further pointed out that there is no relationship between the vaccine and the risk of thrombosis.
contact.
Specifically, this phase 3 randomized, double-blind, placebo-controlled multicenter study involved 32,449 subjects in the United States, Peru, and Chile.
The researchers randomly assigned these subjects to the ZAD1222 group and the placebo group at a ratio of 2:1.
The main results are data on the efficacy, safety, and tolerability of the vaccine.
Among the vaccinated participants, 79% were white, 8% were African American, 4% were Native American, 4% were Asian, and 22% were Hispanic.
Approximately 20% of the participants were 65 years of age and older, and 60% of the participants had comorbidities related to the progression of severe COVID-19, such as diabetes, obesity, or heart disease.
Previous test data showed that extending the time of two vaccination by 12 weeks can show greater vaccine efficacy, which is also supported by immunogenicity data.
In this new trial, the researchers gave participants two doses at an interval of four weeks and found that a four-week interval between vaccination can also further improve the efficacy.
The final analysis showed that the efficacy of the vaccine was consistent among participants of different races and ages.
In the prevention of symptomatic new coronavirus pneumonia (COVID-19), the vaccine has an effective rate of 79%, and it is 100% effective in preventing severe COVID-19 and hospitalization.
In addition, AstraZeneca specifically emphasized the link between vaccines and thrombosis risk in this report.
Among the 21,583 participants who received at least one dose of the vaccine, no risk of thrombosis or events characterized by thrombosis were found.
It is reported that AstraZeneca will continue to analyze the data from the Phase 3 trial and is expected to submit the preliminary analysis results to the U.
S.
Food and Drug Administration (FDA) in the next few weeks for emergency use authorization.
At the same time, the main analysis results will be published in peer-reviewed journals.
End reference materials: [1] AstraZeneca official website
In this regard, AstraZeneca retorted in a statement on March 14 that there is no evidence that there is a connection between the vaccine and thrombosis, and insisted that its new crown vaccine is safe.
On March 22, local time, AstraZeneca’s official website further announced the interim analysis results of the phase 3 clinical trial of the recombinant adenovirus vector vaccine ZAD1222 developed in cooperation with the University of Oxford, and further pointed out that there is no relationship between the vaccine and the risk of thrombosis.
contact.
Specifically, this phase 3 randomized, double-blind, placebo-controlled multicenter study involved 32,449 subjects in the United States, Peru, and Chile.
The researchers randomly assigned these subjects to the ZAD1222 group and the placebo group at a ratio of 2:1.
The main results are data on the efficacy, safety, and tolerability of the vaccine.
Among the vaccinated participants, 79% were white, 8% were African American, 4% were Native American, 4% were Asian, and 22% were Hispanic.
Approximately 20% of the participants were 65 years of age and older, and 60% of the participants had comorbidities related to the progression of severe COVID-19, such as diabetes, obesity, or heart disease.
Previous test data showed that extending the time of two vaccination by 12 weeks can show greater vaccine efficacy, which is also supported by immunogenicity data.
In this new trial, the researchers gave participants two doses at an interval of four weeks and found that a four-week interval between vaccination can also further improve the efficacy.
The final analysis showed that the efficacy of the vaccine was consistent among participants of different races and ages.
In the prevention of symptomatic new coronavirus pneumonia (COVID-19), the vaccine has an effective rate of 79%, and it is 100% effective in preventing severe COVID-19 and hospitalization.
In addition, AstraZeneca specifically emphasized the link between vaccines and thrombosis risk in this report.
Among the 21,583 participants who received at least one dose of the vaccine, no risk of thrombosis or events characterized by thrombosis were found.
It is reported that AstraZeneca will continue to analyze the data from the Phase 3 trial and is expected to submit the preliminary analysis results to the U.
S.
Food and Drug Administration (FDA) in the next few weeks for emergency use authorization.
At the same time, the main analysis results will be published in peer-reviewed journals.
End reference materials: [1] AstraZeneca official website
